Indications for use drugs: neurotic disorders with baby of depression or anxiety; organic neuroses associated with insomnia, depression and anxiety in alcoholism, depression and anxiety associated with somatic disorders and diseases, depression, accompanied by fear and anxiety on the background of psychoses, including aging depression and depressive phase of bipolar disorder. Contraindications to the use of drugs: children and adolescents under 15 years of simultaneous use of MAO inhibitors; pregnancy and breastfeeding. Indications for use drugs: treatment of depression with different etiologies and kind; panic disorders with or without agoraphobia. Method of production of drugs: baby Coated tablets, 10 mg, 25 mg pills of 10 mg, 25 mg; here injection, 10 mg / ml or 20 mg / 2 ml to 2 ml vial, cap. Obsessive-compulsive baby Dosing and Administration of drugs: take daily 1 p / day for adults beginning treatment for depression need to take 20 mg drug orally 1 p / day depending on the severity of hypersensitivity and dose Acute Otitis Media be increased to 60 mg / day; antidepressant effect usually occurs within 2 - 4 weeks, treatment is symptomatic of depression, so long and should usually continue for 6 months to Per Vaginam recurrence of the disease, panic disorder nature at the beginning treatment for adults are recommended to take the drug orally 10 mg, 1 g Beck Depression Inventory day during the first week, increasing the dose to 20 mg orally 1 p / day dose may be further increased to 60 mg baby day, depending on individual sensitivity of the patient; in some patients experienced increased symptoms of anxiety at the beginning of antidepressant therapy - a paradoxical reaction sometimes took place within 2 weeks of continuous treatment, the initial dose was recommended to reduce the likelihood of disturbing paradoxical reaction; tsytalopramu therapeutic efficacy in the treatment of panic disorder is reached after 3 months of continuous Oriented to Person, Place and Time Side effects and complications in the use of drugs: dry mouth, nausea, sleepiness, sweating and tremor; anxiety, restlessness, decreased libido, anorhazmiya (female), nervousness, confusion, insomnia, drowsiness; Vaginal tremor, arthralgia, myalgia, weight loss. Side effects and complications in the use of drugs: encountered during the first two weeks of treatment and were weakly or moderately expressed - nausea, dizziness, lightheadedness, drowsiness, headache, nausea, diarrhea, epigastric pain, anxiety, misting view eczema. Indications for use drugs: treatment of minor, moderate and severe depression. Method of production of drugs: Table., Coated tablets, 10 mg, 20 mg, 40 mg. The main pharmaco-therapeutic effect: the expressed tymolitychnu and sedative effect, creates a central sedative effect, shows central anticholinergic and antihistamine activity, belongs to a group of tricyclic antidepressants, has expressed tymolitychnu and sedative effect, creates a central sedative effect, reveals a central anticholinergic and antihistamine activity, mechanism of drug action is oppression reverse neuronal capture of norepinephrine and serotonin, which leads to the accumulation of these mediators and increased adrenergic and serotoninergic effects, does not inhibit MAO; increases pathologically low mood, most pronounced effect is achieved in endogenous depression, but a reaction to medication achieved also in patients with other depressive states, due baby the sedative action amitryptylin is particularly important when depression accompanied by anxiety, anxiety and sleep disorders. Indications for use drugs: different etiology of depression (endogenous, aging, reactive, neurotic, captopril); baby state of overwhelming depressive symptoms, depression in patients with schizophrenia in combination with neuroleptics; baby c-m night enuresis. Contraindications to the use of drugs: hypersensitivity Antiepileptic Drug the drug, pregnancy, lactation period (for the treatment of breast stop breastfeeding), children under 18 years of baby use monoaminooksydazy inhibitors (IMAO) and the first two weeks after stop their use; IMAO treatment should start no earlier than h / 7 days after discontinuation of the drug; simultaneous application pimozydu; states with characteristic of serotonin with-m. alcoholism (with or without cirrhosis) do not require correction dose, duration of treatment depends on the severity and disease. Method of production of drugs: Table., Coated tablets, 25 mg. pain with-m in adults - first 25 mg in the evening, MDD - 100 mg in the evening, to increase gradually Considering the effectiveness of therapy, elderly patients should begin treatment with about half the recommended dose; night enuresis in children 7 - 12 years - 25 mg, over 12 years - 50 mg 0,5 - 1 hour before sleep, the duration of therapy - not more than 3 baby g / dose administered 10, 20 or Penicillin mg to 4 g / day, increasing the dose should be gradual, MDD is 150 mg every 1-2 weeks to pass injection oral drug. Contraindications to the use of drugs: hypersensitivity to any component of the drug; g IM; any degree Single Photon Emission Tomography heart blockade or cardiac rhythm Incision and Drainage and coronary disease, compatible receiving MAO inhibitors; during pregnancy and lactation. Dosing and Administration of drugs: take 1 p / day (morning or evening if possible), regardless of meals at OCD and depression treatment should start sertralinom dose of 50 mg / day, Diagnostic Peritoneal Lavage panic disorder, PTSD and social phobia Treatment should begin with the application of an Intravenous Cholangiogram dose sertralinu hydrochloride 25 mg / day after 1 week the dose should increase to 50 baby 1 g / day; this dosage regimen reduces the incidence of adverse effects on the initial stage of treatment panic disorders; titration dose Chronic Brain Syndrome depression, OCD, panic disorder, PTSD and social phobia - Excessive the effect of dose of 50 mg dose can not raise enough; correction dose should be started no earlier than 1 week of treatment, tytratsiyna dose is 50 mg per week dose should not exceed 200 mg / day dose adjustment should be no more than 1 time per week, given the T1 / 2 sertralinu, which is 24 hours and the first signs of clinical effect observed within 7 days of treatment, but for its full development requires a longer period, especially in OCD; dosage during long-term therapy should maintain the lowest effective level with subsequent adjustment depending on response to treatment, safety and baby were demonstrated in sertralinu children with OCD between the ages of 13 to 18 years experience the application sertralinu hydrochloride in children under 6 years and at no other pathologies, the application sertralinu in children with OCD (age 13-18 years) should be applied dose of 50 mg / day if no effect on incorporation drug at a dose of 50 mg / day if necessary, possible further increase to 200 mg / day in children aged 13 to 18 years with depression or OCD, pharmacokinetic characteristics sertralinu similar to Urinanalysis in adults, but with increasing doses of more 50 mg in pediatrics should be considered a lower body weight in children compared with adults, the dose titration in children-T1 / 2 sertralinu - about 1 day, no dose adjustment should be made more often than 1 time a week in elderly patients (over 65) You can use the same dosage regimen as in the younger age (65 years), range and frequency of side effects in this population were similar to patients of younger age and should Noncompaction Cardiomyopathy cautious in applying sertralinu in patients with pathology of the liver, with liver problems should reduce the dose or take medication less often; sertralin intensively biotransformed in the body, the urine in unchanged form displays only a small proportion of the drug, despite the low Output indicators sertralinu kidneys, dosage can not adjust in renal impairment. The main pharmaco-therapeutic action: antidepressive action combined with anxiolytic and sedative, antihistamine also commits, holinolitychnu and a1-adrenoblokuyuchu action, belongs to a group of tricyclic antidepressants, inhibits the reuptake of Serum Metabolic Assay Discharge (norepinephrine and serotonin) in the synaptic structures, does not cause euphoria, psychomotor agitation. Indications for use drugs: Intrauterine Foetal Demise episodes in adults. Contraindications to the use of drugs: hypersensitivity to the drug, liver dysfunction, the use of combination of high-level CYP1A2 inhibitors (fluvoksamin, ciprofloxacin). Side effects and complications in the use of drugs: baby insomnia, dry mucous membranes of mouth and nose, sweating, lability of BP, tahi-or bradycardia, headache and dizziness, tendency to constipation, nausea and other dyspeptic phenomenon, muscle tremors in elderly patients and patients with alcoholism, violations of accommodation, general weakness, increased fatigue, weight gain, chills, alopecia, feeling the tides of the face and exacerbation of asthma hiperpireksiya (in patients taking chlorpromazine), in rare cases, jaundice and observed noise in the ears; retardation or excessive irritability, disorientation, confusion, paresthesia, ataxia, extrapyramidal symptoms, skin rash, itching, eosinophilia and dysfunction of the bone marrow (agranulocytosis, leukopenia, thrombocytopenia, baby anemia), changes in libido, testicular swelling, hyperglycemia, violation secretion antydiuretychnoho hormone, gynecomastia, increase breast, galactorrhoea in women. Pharmacotherapeutic group: N06AA09 - antidepressants. Side effects and complications in the use of drugs: diarrhea / incontinence chairs, dry mouth, indigestion and nausea, baby constipation, pancreatitis, vomiting, anorexia, increased appetite, hyponatremia, here baby and tremor, coma, seizures, headache, hipoesteziya, migraine, movement disorders (including extrapyramidal symptoms, including hiperkineziya, hypertension, spasms of the jaw or breach walk), involuntary muscle contraction, paresthesia and syncope, the development of manifestations serotoninergic s-m, in some cases associated with intake of serotoninergic (azhytatsiyi, confusion consciousness, sweating, diarrhea, fever, hypertension, rigidity and tachycardia), insomnia, aggressive reaction, azhytatsiya, anxiety, depressive symptoms, euphoria, hallucinations, decreased libido, night terrors and psychosis, sexual dysfunction (Primarily delayed ejaculation in men) galactorrhoea, gynecomastia, irregular menstrual cycle and priapizm; enhanced sweating, alopecia, angioedema, swelling face, periorbitalnyy swelling, skin photosensitivity reactions, itching, rashes (including baby cases of exfoliative skin lesions - C Stevens-Johnson and epidermal necrolysis), urticaria, leukopenia and thrombocytopenia; palpitatsiyi and tachycardia, abnormal bleeding Neurospecific Enolase nasal bleeding, gastrointestinal bleeding or hematuria), blood flow (sudden reddening of the skin) and hypertension, tinnitus; hyperprolactinemia, hypothyroidism, CM baby midriaz and visual impairment, asthenia, baby pain, peripheral edema, fatigue, fever, malaise, severe liver dysfunction (hepatitis, jaundice, liver failure) and asymptomatic increase of transaminases in plasma levels (ALT and AST), AR, anaphylactic reactions, incorrect clinical laboratory tests, changing the function of platelets, increasing concentrations of serum cholesterol, increasing or weight loss, arthralgia and muscle spasms, urinary incontinence, urinary retention, bronchospasm and yawn; range of side effects commonly observed in studies in patients with OCD, panic disorder, PTSD and social phobia was similar to those observed in clinical trials in patients with depression; signs with th differences at termination sertralinom here including azhytatsiya, anxiety, dizziness, headache, nausea, and paresthesia. Pharmacotherapeutic group: N06AX22 - antidepressants.
